Article Versions Notes

Avilés-Salas A, Díaz-García DA, Lara-Mejía L, Cardona AF, Orozco-Morales M, Catalán R, Hernández-Pedro NY, Rios-Garcia E, Ramos-Ramírez M, Arrieta O. LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer. Current Oncology. 2023; 30(1):333-343. https://doi.org/10.3390/curroncol30010027

Avilés-Salas, Alejandro, Diego A. Díaz-García, Luis Lara-Mejía, Andrés F. Cardona, Mario Orozco-Morales, Rodrigo Catalán, Norma Y. Hernández-Pedro, Eduardo Rios-Garcia, Maritza Ramos-Ramírez, and Oscar Arrieta. 2023. "LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer" Current Oncology 30, no. 1: 333-343. https://doi.org/10.3390/curroncol30010027

Avilés-Salas, A., Díaz-García, D. A., Lara-Mejía, L., Cardona, A. F., Orozco-Morales, M., Catalán, R., Hernández-Pedro, N. Y., Rios-Garcia, E., Ramos-Ramírez, M., & Arrieta, O. (2023). LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer. Current Oncology, 30(1), 333-343. https://doi.org/10.3390/curroncol30010027